The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization and impact of B7-H3 (CD276) expression across disease states and racial groups in prostate cancer.
 
Justin Hwang
Consulting or Advisory Role - Astrin Bio; Tempus
Research Funding - Astrin Biosciences
 
Nishant Gandhi
Employment - Caris Life Sciences
 
Allison Makovec
No Relationships to Disclose
 
Norm Smith
Employment - Caris Life Sciences
 
Andrew Elliott
Employment - Caris Life Sciences
 
Vivek Narayan
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca; Eisai; Exelixis; Janssen Oncology; Merck; Myovant Sciences; Pfizer/Astellas; Regeneron; Sanofi; Terns Pharmaceuticals; Xencor
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - US Patent No. 18/708,529
Travel, Accommodations, Expenses - Eisai; Exelixis; Pfizer
 
Eugene Shenderov
No Relationships to Disclose
 
Elisabeth Heath
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Johnson & Johnson/Janssen; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; EMD Serono; Gilead Sciences; Novartis; Sanofi
Speakers' Bureau - Sanofi
Research Funding - Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Calithera Biosciences (Inst); Caris Life Sciences (Inst); Corcept Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo Inc. (Inst); Eisai (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen Research & Development (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); POINT Biopharma (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Sanofi
Other Relationship - Caris Centers of Excellence
 
Nicholas Zorko
Consulting or Advisory Role - Bayer; Dendreon; Takeda (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Telix Pharmaceuticals
 
Emmanuel Antonarakis
Consulting or Advisory Role - AADi; AIkido Pharma; Amgen; AstraZeneca; Bayer (Inst); Blue Earth Diagnostics; Corcept Therapeutics; Curium Pharma; Foundation Medicine; Hookipa Pharma; Janssen Biotech; Lilly; Menarini Silicon Biosystems; Merck; Pfizer; Sanofi; Tango Therapeutics; Tempus; Z-Alpha
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Macrogenics (Inst); Merck (Inst); Orion Health (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
 
Rana McKay
Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)